Grifols S.A. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (22)

Latest Posts

About This Stock More About This Stock
Grifols Announces FDA Approval Of Subcutaneous Immunoglobulin Xembify
Article By: The Fly
Thursday, July 4, 2019 4:25 PM EDT
The company plans to launch Xembify in the United States in the last quarter of 2019 and is working with healthcare authorities to obtain approval in Canada, Europe, and other markets.
In this article: GRFS
Read
Week In Review: Grifols Pays $1.9 Billion For 26% Stake In Shanghai RAAS
Article By: ChinaBio® Today
Saturday, March 9, 2019 4:13 PM EDT
Grifols, a Barcelona maker of plasma-based medicines, acquired a 26% stake in Chinese blood plasma company Shanghai RAASfor $1.9 billion in a non-cash deal. Grifols will exchange a 45% ownership in Grifols Diagnostic Solutions for the RAAS stake.
In this article: CASI, BGNE, GRFS, NVO
Read
Grifols In Talks For $5B Stake In China's Shanghai RAAS Blood Products
Article By: The Fly
Friday, November 23, 2018 11:30 AM EDT
Grifols would invest in Shanghai RAAS by means of the contribution of its fully owned U.S. subsidiary, Grifols Diagnostic Solutions.
In this article: GRFS
Read
Grifols, S.A.: Success Is In Its Blood
Article By: Fredrik Arnold
Friday, February 23, 2018 6:59 AM EDT
Today I'm reviewing a biotechnology company, Grifols, S.A. Its trading ticker symbol is GRFS.
In this article: GRFS
Read
3 Biotechnology Stocks To Buy On This Biotechnology Breakout
Article By: Taki Tsaklanos
Thursday, June 22, 2017 9:11 PM EDT
The biotechnology stock sector is breaking out. After 20 months of consolidation “everyone” forgot about biotechnology stocks, the former leading stock market sector. As it always goes the bull breaks out once all interest is gone.
In this article: RGEN, AMGN, GRFS
Read

PARTNER HEADLINES

Latest Tweets for $GRFS

No tweets yet!